SSScott A. Strassels

Scott A. Strassels

*This is an algorithmically generated author record based on publicly available information.

Scott A. Strassels has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Associations of Cancer Patients' Demographic and Clinical Characteristics With Cannabis-Related Interest and Behaviors

    by Neema C. Adley, Theodore M. Brasky, Sara R. Conroy, Alison M. Newton, Jesse J. Plascak, Scott A. Strassels, John L. Hays, Jessica L. Krok-Schoen

    Background: Cannabis interest and use is increasing in the United States, yet research on its use among cancer patients is limited. Methods: Individuals with cancer completed an anonymous cross-sectional questionnaire. Multivariable logistic regressions estimated odds ratios (OR) between patients' demographic and clinical characteristics with cannabis-related interest, current use, and provider recommendation. Results: Participants (n = 943) were, on average, 61.7 years old. Older patients were less likely to use cannabis products (OR = 0.42, confidence interval [95% CI]: 0.26–0.69) and less likely to be interested in cannabis (OR = 0.60, 95% CI: 0.44–0.84) than younger patients. Those with higher education were less likely to be using cannabis (OR = 0.41, 95% CI: 0.25–0.67) and less likely to have received a provider recommendation of cannabis use than the least educated (OR = 0.38, 95% CI: 0.19–0.76). Cancer spread and type were significant correlates of provider recommendation of cannabis use. Conclusions: Additional research is warranted to better understand cancer patients' motivations for cannabis use and interest.


  • Cannabis use and symptom management among older adults with cancer

    by J. Krok-Schoen, A. Newton, S. Conroy, A. Adib, N. Adley, S. Strassels, J. Hays, Z. Cooper, T. Wagener, E. Stevens, et al.

  • Open Access

    Data from Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer

    by Theodore M. Brasky, Alison M. Newton, Sara Conroy, Anita Adib, Neema C. Adley, Scott A. Strassels, John L. Hays, Ziva D. Cooper, Theodore L. Wagener, Erin Stevens, et al.

    Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population.Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use.Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use.This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.Significance:Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.

  • Open Access

    Data from Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer

    by Theodore M. Brasky, Alison M. Newton, Sara Conroy, Anita Adib, Neema C. Adley, Scott A. Strassels, John L. Hays, Ziva D. Cooper, Theodore L. Wagener, Erin Stevens, et al.

    Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population.Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use.Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use.This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.Significance:Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.

  • Open Access

    Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer

    by Theodore M. Brasky, Alison M. Newton, Sara Conroy, Anita Adib, Neema C. Adley, Scott A. Strassels, John L. Hays, Ziva D. Cooper, Theodore L. Wagener, Erin Stevens, et al.

    Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population.Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use.Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use.This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations.Significance: Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.


  • The siren's song of anonymous web‐based sampling

    by Theodore M. Brasky, Jessica L. Krok‐Schoen, Sara Conroy, Alison M. Newton, Scott A. Strassels, John L. Hays, Theodore L. Wagener


  • Open Access

    Opioid Taper Practices Among Clinicians

    by Amelia L Persico, Jeffrey J Bettinger, Erica L Wegrzyn, Jeffrey Fudin, Scott A Strassels

    Introduction: Opioid dose tapers are used frequently when cross-titrating from one or more opioids to another or when discontinuing therapy. Currently, there is no universally accepted evidence-based standard of care for this procedure which can leave patients at risk for withdrawal symptoms, inadequate pain control, or elevated suicide risk. Objective: The objective of this study was to examine practices and rationale among clinicians, to determine if there is a difference among respondents in their comfort level, method and rationale for tapering opioids at various morphine milligram equivalents (MME) and to assess the need for the development of a standard of care. Methods: Data were derived from an electronic survey developed using SurveyMonkey®. The survey was disseminated via e-mail listservs, social media, and professional organizations. Data were collected regarding profession, confidence tapering opioids at varying total MME, method and rationale for tapering, and pharmacologic management of withdrawal symptoms. Pearson’s Chi squared and Fisher’s exact tests were used to assess statistical significance of results. Results: A total of 149 clinicians completed the survey, physicians, NPs, pharmacists, and PAs accounted for 51%, 20%, 19%, and 10% of participants, respectively. Overall, 55% of the respondents self-identified as pain specialists. There were no statistically significant differences in reported comfort level among the different types of providers. Nearly 50% of participants indicated their rationale for tapering or discontinuing opioids was the 2016 CDC guidelines. Conclusion: Despite that the majority of providers surveyed self-identified as pain specialists, over 50% were not comfortable tapering opioids at doses greater than 120 MME/day. This observation suggests a need for further education and establishment of consensus guidelines on method and rationale for opioid tapering. Provider motivation for tapering was largely influenced by CDC guidelines based on low quality evidence. This strengthens the argument for the creation of guidelines based on high quality evidence.


  • Hospital Admissions Associated With Cancer Pain in Older Adults With and Without Dementia

    by Scott A. Strassels, Karen O. Moss, Peter J. Mallow, Robert M. Tamer, Todd B. Monroe, Nicole O. Williams, Ann S. Levine, Ulrike Muench


  • The Need for Accurate Risk Assessment in a High-Risk Patient Population: A NSQIP Study Evaluating Outcomes of Cholecystectomy in the Patient With Cancer

    by Gregory Metzger, Chelsea Horwood, J.C. Chen, Ryan Eaton, Scott A. Strassels, Robert M. Tamer, Jonathan Wisler, Heena Santry, Amy Rushing


  • Analyzing Outcomes Among Older Adults With Necrotizing Soft-Tissue Infections in the United States

    by Adara R. McCarty, Michael E. Villarreal, Robert Tamer, Scott A. Strassels, Kathryn M. Schubauer, Anghela Z. Paredes, Heena Santry, Jon R. Wisler